Cardiogeni (AQSE:CGNI) OCF Yield %: 0.00 (As of Sep. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cardiogeni OCF Yield %?

Cardiogeni AQSE:CGNI OCF Yield % is 0.00 as of Sep. 11, 2026.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Cardiogeni's Trailing 12-Month Cash Flow from Operations is £0.00 Mil, and Market Cap is £5.97 Mil. Therefore, Cardiogeni's OCF Yield % for today is 0.00%.

The historical rank and industry rank for Cardiogeni's OCF Yield % or its related term are showing as below:


AQSE:CGNI's OCF Yield % is not ranked *
in the Biotechnology industry.
Industry Median: -8.34
* Ranked among companies with meaningful OCF Yield % only.

Cardiogeni's OCF Margin % for the quarter that ended in . 20 was %.

Cardiogeni OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Cardiogeni OCF Yield % Related Terms

Cardiogeni OCF Yield % Historical Data

* Premium members only.

The historical data trend for Cardiogeni's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiogeni OCF Yield % Chart

Cardiogeni Annual Data
Trend
OCF Yield %

Cardiogeni Semi-Annual Data
OCF Yield %

Cardiogeni OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Cardiogeni's OCF Yield % for the fiscal year that ended in . 20 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
= /
=N/A%

Cardiogeni's annualized OCF Yield % for the quarter that ended in . 20 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
= * 1 /
=N/A%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of 0.00 mean?
Cardiogeni (AQSE:CGNI) has a OCF Yield % of 0.00 as of Sep. 11, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Cardiogeni and its competitors.
Is Cardiogeni's OCF Yield % too high?
Cardiogeni's current OCF Yield % is 0.00.
How does Cardiogeni's OCF Yield % compare to ?
Cardiogeni's OCF Yield % of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Cardiogeni and its competitors. Cardiogeni's current OCF Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiogeni stock overvalued right now?
Cardiogeni (AQSE:CGNI) has a current OCF Yield % of 0.00. The current OCF Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Cardiogeni (AQSE:CGNI), the current OCF Yield % is 0.00 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiogeni Business Description

Comparable Companies
Address Celixir House Stratford-Upon-Avon Business & Technology Park, Innovation Way, Stratford upon Avon, GBR, CV37 7GZ
Cardiogeni PLC is engaged in the development and commercialisation of a portfolio of novel cellular medicines for heart failure. The Company focuses on the development and commercialisation of novel cellular medicines targeting early- and mid-stage heart failure. Its strategic priority is to complete a pivotal Phase 2b/3 study and obtain first market approval for its product, CLXR-001, in a suitable jurisdiction, and then establish strategic funding and collaboration agreements to develop and commercialise the product in the US, EU, Japan, and other jurisdictions.